Emergent BioSolutions | Betriebsaufwand



Operating Expenses Veränderung Datum
Acadia Pharmaceuticals USD 225.03M 118.93M 2025-03
ALKERMES USD 292.72M 25.42M 2025-03
Alnylam Pharmaceuticals USD 576.11M 122.21M 2025-03
Amarin USD 58.77M 56.06M 2025-03
ANI Pharmaceuticals USD 170.93M 24.02M 2025-03
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Exact Sciences USD 802.8M 786.98M 2025-03
Exelixis USD 368.59M 34.96M 2025-04
Glaxosmithkline GBP 7.42B 408M 2024-12
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Lonza CHF 3.09B 564M 2024-12
Merck USD 9.66B 1.67B 2025-03
Moderna USD 1.16B 1.06B 2025-03
Myriad Genetics USD 224.9M 24.7M 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pacira USD 166.93M 4.38M 2025-03
Pfizer USD 10.05B 8.12B 2025-03
PTC Therapeutics USD 205.87M 69.79M 2025-03
Sanofi EUR 8.32B 1.55B 2025-03
Sarepta Therapeutics USD 1.05B 548.51M 2025-03
United Therapeutics USD 411.6M 33.4M 2025-03



Emergent BioSolutions Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Jul 2025.